The mouse bioassay (MBA) for paralytic shellfish toxins (PSTs) in bivalves has been used as an official methodology in Japan. It’s essential to develop another methodology to animal experiments in PSTs assay as a result of 3Rs (Substitute, Discount, and Refinement) of animal experiments are required from the animal welfare standpoint. Numerous strategies corresponding to HPLC-FL, receptor binding assay, LC-MS/MS and ELISA have been established to detect PSTs with out performing animal experiments.
The current examine was undertaken to develop a screening methodology utilizing oligonucleotide lateral move immunoassay (OLFIA) for detecting PSTs in bivalves. The screening stage was outlined as optimistic at 2 MU/g of MBA that’s the half regulation restrict of PSTs monitoring in Japan. All 20 optimistic (equal to or greater than 2 MU/g) samples judged from MBA confirmed a optimistic response within the OLFIA. No optimistic samples resulted in a false detrimental response. The OLFIA exhibited excessive accuracy at 2 MU/g of screening standards. The authors demonstrated right here that the OLFIA may be helpful for speedy detection of PSTs in bivalves.
Therapeutic oligonucleotides require the addition of a number of chemical modifications to the nucleosidic scaffold with a purpose to enhance their drug supply effectivity, cell penetration capability, organic stability, and pharmacokinetic properties. This chemical modification sample is commonly accompanied by an artificial burden and by limitations in sequence size. Right here, we now have synthesized a nucleoside triphosphate analog bearing two simultaneous modifications on the stage of the sugar (LNA) and the spine (thiophosphate) and have examined its compatibility with enzymatic DNA synthesis which may abrogate a few of these artificial limitations.
Whereas this novel analog shouldn’t be as nicely tolerated by polymerases in comparison with the corresponding α-thio-dTTP or LNA-TTP, α -thio-LNA-TTP can readily be used for enzymatic synthesis on common templates for the introduction of phosphorothioated LNA nucleotides.
Advances of Antisense Oligonucleotide Know-how within the Remedy of Hereditary Neurodegenerative Illnesses
Antisense nucleic acids are single-stranded oligonucleotides which were specifically chemically modified, which may bind to RNA expressed by goal genes by base complementary pairing and have an effect on protein synthesis on the stage of posttranscriptional processing or protein translation. Lately, the appliance of antisense nucleic acid expertise within the therapy of neuromuscular illnesses has made outstanding progress. In 2016, the US FDA permitted two antisense nucleic acid medicine for the therapy of Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), and the event to deal with different neurodegenerative illnesses has additionally entered the medical stage.
Due to this fact, ASO represents a therapy with nice potential. The article will summarize ASO therapies when it comes to mechanism of motion, chemical modification, and administration strategies and analyze their function in a number of widespread neurodegenerative illnesses, corresponding to SMA, DMD, and amyotrophic lateral sclerosis (ALS).
This text systematically summarizes the nice potential of antisense nucleic acid expertise within the therapy of hereditary neurodegenerative illnesses. Dengue fever is among the commonest viral infections affecting people. It’s an increasing public well being drawback, significantly in tropical and subtropical areas. No efficient vaccine or antiviral therapies in opposition to Dengue virus (DENV) an infection can be found. Due to this fact, there’s a robust must develop secure and efficient therapeutic methods that may cut back the burden and length of hospitalizations as a consequence of this life-threatening illness.
A number of antisense oligonucleotides focused in opposition to monoacylglycerol acyltransferase 1 (Mogat1) enhance glucose metabolism independently of Mogat1
Niban (FAM129A) Antibody |
|||
abx020066-100ug | Abbexa | 100 ug | EUR 526.8 |
Anti-FAM129A antibody |
|||
PAab02964 | Lifescience Market | 100 ug | EUR 426 |
Human Protein FAM129A (FAM129A) ELISA Kit |
|||
abx387256-96tests | Abbexa | 96 tests | EUR 1093.2 |
FAM129A siRNA |
|||
20-abx901841 | Abbexa |
|
|
FAM129A siRNA |
|||
20-abx916028 | Abbexa |
|
|
FAM129A siRNA |
|||
20-abx916029 | Abbexa |
|
|
anti-FAM129A |
|||
LF-PA20345 | Abfrontier | 100 ul | EUR 400.8 |
Description: Rabbit polyclonal to FAM129A |
Phospho-FAM129A (Ser602) Antibody |
|||
CSB-PA589975-100ul | Cusabio | 100ul | EUR 434.4 |
Description: A polyclonal antibody against Phospho-FAM129A (Ser602). Recognizes Phospho-FAM129A (Ser602) from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:1000 |
Phospho-FAM129A (Ser602) Antibody |
|||
CSB-PA589975- | Cusabio | each | EUR 402 |
Description: A polyclonal antibody against Phospho-FAM129A (Ser602). Recognizes Phospho-FAM129A (Ser602) from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:1000 |
FAM129A cloning plasmid |
|||
CSB-CL883649HU-10ug | Cusabio | 10ug | EUR 1066.8 |
Description: A cloning plasmid for the FAM129A gene. |
FAM129A Blocking Peptide |
|||
33R-8947 | Fitzgerald | 100 ug | EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FAM129A antibody, catalog no. 70R-1294 |
Anti-Phospho-FAM129A-(S602) antibody |
|||
STJ22138 | St John's Laboratory | 100 µl | EUR 471.6 |
Description: This gene encodes a member of the family with sequence similarity 129 protein family. This gene is highly expressed in several cancer cells and may serve as a prognostic marker for certain cancers. The encoded protein may play a role in regulating p53-mediated apoptosis. |
Rat FAM129A shRNA Plasmid |
|||
20-abx986118 | Abbexa |
|
|
Mouse FAM129A shRNA Plasmid |
|||
20-abx975234 | Abbexa |
|
|
Human FAM129A shRNA Plasmid |
|||
20-abx964521 | Abbexa |
|
|
FAM129A ELISA KIT|Human |
|||
EF009516 | Lifescience Market | 96 Tests | EUR 826.8 |
Polyclonal FAM129A / NIBAN Antibody (aa908-920) |
|||
APR02341G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FAM129A / NIBAN (aa908-920). This antibody is tested and proven to work in the following applications: |
Phospho-FAM129A-S602 Rabbit pAb |
|||
AP0350-100ul | Abclonal | 100 ul | EUR 460.8 |
Phospho-FAM129A-S602 Rabbit pAb |
|||
AP0350-200ul | Abclonal | 200 ul | EUR 664.8 |
Phospho-FAM129A-S602 Rabbit pAb |
|||
AP0350-20ul | Abclonal | 20 ul | Ask for price |
Phospho-FAM129A-S602 Rabbit pAb |
|||
AP0350-50ul | Abclonal | 50 ul | EUR 318 |
Fam129a ORF Vector (Rat) (pORF) |
|||
ORF066801 | ABM | 1.0 ug DNA | EUR 607.2 |
FAM129A ORF Vector (Human) (pORF) |
|||
ORF003782 | ABM | 1.0 ug DNA | EUR 114 |
Fam129a ORF Vector (Mouse) (pORF) |
|||
ORF044312 | ABM | 1.0 ug DNA | EUR 607.2 |
FAM129A sgRNA CRISPR Lentivector set (Human) |
|||
K0745601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Human Protein Niban, FAM129A ELISA KIT |
|||
ELI-38137h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse Protein Niban, Fam129a ELISA KIT |
|||
ELI-13123m | Lifescience Market | 96 Tests | EUR 1038 |
Fam129a sgRNA CRISPR Lentivector set (Rat) |
|||
K7119001 | ABM | 3 x 1.0 ug | EUR 406.8 |
Fam129a sgRNA CRISPR Lentivector set (Mouse) |
|||
K4582201 | ABM | 3 x 1.0 ug | EUR 406.8 |
Rabbit Anti-Human FAM129A (aa 160-175) Polyclonal Antibody |
|||
CPB-1201RH | Creative Diagnostics | 100 ul | EUR 552 |
Family With Sequence Similarity 129, Member A (FAM129A) Antibody |
|||
20-abx112435 | Abbexa |
|
|
Family With Sequence Similarity 129, Member A (FAM129A) Antibody |
|||
abx232964-100ug | Abbexa | 100 ug | EUR 577.2 |
Family with Sequence Similarity 129, Member A (FAM129A) Antibody |
|||
abx330391-100ul | Abbexa | 100 ul | EUR 510 |
FAM129A sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
K0745602 | ABM | 1.0 ug DNA | EUR 184.8 |
FAM129A sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K0745603 | ABM | 1.0 ug DNA | EUR 184.8 |
FAM129A sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K0745604 | ABM | 1.0 ug DNA | EUR 184.8 |
Fam129a sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
K7119002 | ABM | 1.0 ug DNA | EUR 184.8 |
Fam129a sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
K7119003 | ABM | 1.0 ug DNA | EUR 184.8 |
Fam129a sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
K7119004 | ABM | 1.0 ug DNA | EUR 184.8 |
Fam129a sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
K4582202 | ABM | 1.0 ug DNA | EUR 184.8 |
Fam129a sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K4582203 | ABM | 1.0 ug DNA | EUR 184.8 |
Fam129a sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
K4582204 | ABM | 1.0 ug DNA | EUR 184.8 |
FAM129A Protein Vector (Human) (pPB-C-His) |
|||
PV015125 | ABM | 500 ng | EUR 394.8 |
FAM129A Protein Vector (Human) (pPB-N-His) |
|||
PV015126 | ABM | 500 ng | EUR 394.8 |
FAM129A Protein Vector (Human) (pPM-C-HA) |
|||
PV015127 | ABM | 500 ng | EUR 394.8 |
FAM129A Protein Vector (Human) (pPM-C-His) |
|||
PV015128 | ABM | 500 ng | EUR 394.8 |
FAM129A Protein Vector (Mouse) (pPB-C-His) |
|||
PV177246 | ABM | 500 ng | EUR 1278 |
FAM129A Protein Vector (Mouse) (pPB-N-His) |
|||
PV177247 | ABM | 500 ng | EUR 1278 |
FAM129A Protein Vector (Mouse) (pPM-C-HA) |
|||
PV177248 | ABM | 500 ng | EUR 1278 |
FAM129A Protein Vector (Mouse) (pPM-C-His) |
|||
PV177249 | ABM | 500 ng | EUR 1278 |
FAM129A Protein Vector (Rat) (pPB-C-His) |
|||
PV267202 | ABM | 500 ng | EUR 1399.2 |
FAM129A Protein Vector (Rat) (pPB-N-His) |
|||
PV267203 | ABM | 500 ng | EUR 1399.2 |
FAM129A Protein Vector (Rat) (pPM-C-HA) |
|||
PV267204 | ABM | 500 ng | EUR 1399.2 |
FAM129A Protein Vector (Rat) (pPM-C-His) |
|||
PV267205 | ABM | 500 ng | EUR 1399.2 |
FAM129A 3'UTR Luciferase Stable Cell Line |
|||
TU007554 | ABM | 1.0 ml | EUR 2799.6 |
Fam129a 3'UTR Luciferase Stable Cell Line |
|||
TU204267 | ABM | 1.0 ml | Ask for price |
Fam129a 3'UTR GFP Stable Cell Line |
|||
TU254267 | ABM | 1.0 ml | Ask for price |
Fam129a 3'UTR GFP Stable Cell Line |
|||
TU156139 | ABM | 1.0 ml | Ask for price |
Fam129a 3'UTR Luciferase Stable Cell Line |
|||
TU106139 | ABM | 1.0 ml | Ask for price |
FAM129A 3'UTR GFP Stable Cell Line |
|||
TU057554 | ABM | 1.0 ml | EUR 2799.6 |
FAM129A Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
LV626755 | ABM | 1.0 ug DNA | EUR 1626 |
FAM129A Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
LV626759 | ABM | 1.0 ug DNA | EUR 1626 |
FAM129A Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
LV626760 | ABM | 1.0 ug DNA | EUR 1626 |
Family with Sequence Similarity 129, Member A Phospho-Ser602 (FAM129A pS602) Antibody |
|||
abx332930-100ul | Abbexa | 100 ul | EUR 560.4 |
FAM129A sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
K0745605 | ABM | 3 x 1.0 ug | EUR 451.2 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
K7119005 | ABM | 3 x 1.0 ug | EUR 451.2 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
K4582205 | ABM | 3 x 1.0 ug | EUR 451.2 |
FAM129A sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
K0745606 | ABM | 1.0 ug DNA | EUR 200.4 |
FAM129A sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
K0745607 | ABM | 1.0 ug DNA | EUR 200.4 |
FAM129A sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
K0745608 | ABM | 1.0 ug DNA | EUR 200.4 |
FAM129A Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
LV626756 | ABM | 1.0 ug DNA | EUR 1626 |
FAM129A Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
LV626757 | ABM | 1.0 ug DNA | EUR 1695.6 |
FAM129A Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
LV626758 | ABM | 1.0 ug DNA | EUR 1695.6 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
K7119006 | ABM | 1.0 ug DNA | EUR 200.4 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
K7119007 | ABM | 1.0 ug DNA | EUR 200.4 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
K7119008 | ABM | 1.0 ug DNA | EUR 200.4 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
K4582206 | ABM | 1.0 ug DNA | EUR 200.4 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
K4582207 | ABM | 1.0 ug DNA | EUR 200.4 |
Fam129a sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
K4582208 | ABM | 1.0 ug DNA | EUR 200.4 |
ASAP1 antibody Antibody |
|||
DF8746 | Affbiotech | 200ul | EUR 420 |
CD11b Antibody Antibody |
|||
ABD2911 | Lifescience Market | 100 ug | EUR 525.6 |
anti- Antibody^Polyclonal antibody control antibody |
|||
LSMab09882 | Lifescience Market | 100 ug | EUR 525.6 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
F54788-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
ARHGDIA Antibody / RHOGDI Antibody |
|||
F54788-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Antibody |
|||
A1360-500 | Biovision | each | Ask for price |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx123734 | Abbexa |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|||
20-abx004855 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx014333 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx008109 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx033330-400ul | Abbexa | 400 ul | EUR 627.6 |
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx033330-80l | Abbexa | 80 µl | EUR 343.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
abx036399-100ug | Abbexa | 100 ug | EUR 469.2 |
Anti-Glycolipid Antibody (AGA) Antibody |
|||
abx230204-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319900 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319901 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319905 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|||
20-abx319913 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx311665 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
20-abx324434 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|||
abx234901-100ug | Abbexa | 100 ug | EUR 661.2 |
Anti-Anti-SEPT6 antibody antibody |
|||
STJ11100949 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
|||
STJ111369 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ111530 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT4 Antibody antibody |
|||
STJ112276 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-MARCH9 Antibody antibody |
|||
STJ112609 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ25475 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ25477 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ25479 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT2 Antibody antibody |
|||
STJ28365 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ28963 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT1 antibody antibody |
|||
STJ119580 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
Anti-Anti-SEPT12 Antibody antibody |
|||
STJ117759 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118549 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH6 Antibody antibody |
|||
STJ118550 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-MARCH7 Antibody antibody |
|||
STJ118752 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT3 Antibody antibody |
|||
STJ118990 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ113941 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT11 Antibody antibody |
|||
STJ114081 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT5 Antibody antibody |
|||
STJ114819 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-MARCH8 Antibody antibody |
|||
STJ114828 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-Anti-SEPT7 Antibody antibody |
|||
STJ116214 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
|||
STJ117206 | St John's Laboratory | 100 µl | EUR 332.4 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
CLCN5 Antibody / CIC-5 antibody |
|||
RQ6462 | NSJ Bioreagents | 100ug | EUR 419 |
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene. |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
48169-100ul | SAB | 100ul | EUR 399.6 |
Cytokeratin 7 antibody-Cytoskeleton Marker Antibody |
|||
48169-50ul | SAB | 50ul | EUR 286.8 |
Antibody Pair to ApoA-V antibody |
|||
10R-1876 | Fitzgerald | 100 ul | EUR 781.2 |
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
065-A-01mg | Virogen | 0,1 mg | EUR 321 |
Description: anti-CD22 monoclonal antibody |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
|||
065-A-1000ug | Virogen | 1000 ug | EUR 1539 |
Description: anti-CD22 monoclonal antibody |
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103034 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103035 | Abbexa |
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
|||
20-abx103036 | Abbexa |
|
|
Hepatitis C Virus Antibody (HCV) Antibody |
|||
abx023924-1mg | Abbexa | 1 mg | EUR 1446 |
Anti-Glycoprotein 210 Antibody (gp210) Antibody |
|||
abx233571-100ug | Abbexa | 100 ug | EUR 577.2 |
Anti Deoxyribonucleic Acid Antibody (DNA) Antibody |
|||
abx411057-50ug | Abbexa | 50 ug | EUR 710.4 |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319902 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319903 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319904 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319906 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319907 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319908 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319914 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319915 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319916 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
|||
20-abx319929 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
|||
20-abx319930 | Abbexa |
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
|||
20-abx319931 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
|||
20-abx311666 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
|||
20-abx311667 | Abbexa |
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
|||
20-abx311668 | Abbexa |
|
|
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
|||
AMM06679G | Leading Biology | 0.05mg | EUR 633.6 |
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
Goat anti- human Antibody^Polyclonal antibody |
|||
LSMab09896 | Lifescience Market | 100 ug | EUR 525.6 |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D | Stressmarq | 0.1mg | EUR 424.8 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A390 | Stressmarq | 0.1mg | EUR 481.2 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A488 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
Antibody for Human alpha Tubulin Antibody |
|||
SPC-692D-A565 | Stressmarq | 0.1mg | EUR 480 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |